BAX vs PEN: Which Stock Is the Better Buy?
Baxter International Inc. and Penumbra, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BAX vs PEN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Baxter International Inc. (BAX) | Penumbra, Inc. (PEN) | |
|---|---|---|
| Market cap | $11.7B | $12.6B |
| Revenue (latest FY) | $11.24B | $1.40B |
| Net income (latest FY) | $-957.00M | $177.69M |
| Revenue growth (5y CAGR) | -0.7% | 20.2% |
| Net margin | -8.5% | 12.7% |
| Return on equity | -15.6% | 12.4% |
| P/E ratio | — | 73.8 |
| Dividend yield | 0.9% | — |
| Profitable years (of last 10) | 7 | 8 |
| Positive free cash flow | Yes | Yes |
See the full BAX vs PEN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BAX's full financials → Open PEN's full financials →More comparisons
Frequently asked questions
Which is bigger, BAX or PEN?
Penumbra, Inc. is larger by market capitalization — $12.6B versus $11.7B.
Which grows faster, BAX or PEN?
Over the last five fiscal years, Penumbra, Inc. grew revenue faster — 20.2%/yr versus -0.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
BAX fundamentals → · PEN fundamentals → · All 1,500+ companies → · Free screener →